{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:29:50Z","timestamp":1793734190133,"version":"4.6.1"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>With the rising prevalence of diabetes mellitus globally, vision-threatening diabetic retinopathy (DR) is also rapidly increasing. Due to the advent of newer instrumentation, the indications of pars plana vitrectomy (PPV) in such advanced DR patients have also expanded. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are also increasingly being used in patients with DR, often as an adjunct to PPV. This narrative review was conducted to summarize and critically analyze the role of perioperative anti-VEGF therapy in diabetic vitrectomy. Various indications of diabetic vitrectomy where perioperative anti-VEGF is used have been elucidated. Controversies regarding the optimal timing of preoperative anti-VEGF therapy prior to vitrectomy have been addressed in detail. This review also elaborates the various intraoperative and postoperative benefits of anti-VEGFs with regard to the duration of vitrectomy, intraoperative bleeding, iatrogenic breaks, need for endodiathermy and silicon oil endotamponade, surgical difficulty score, postoperative visual gain, intraocular pressures, postoperative vitreous cavity hemorrhage, and need for second surgery. The current narrative also mentions the potential ocular adverse effects of anti-VEGF, such as progression of tractional retinal detachment, apart from addressing other ocular side effects and a few other uncommon yet serious systemic adverse events.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3360_25","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:02:06Z","timestamp":1773331326000},"page":"681-689","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative anti-vascular endothelial growth factor treatment in diabetic vitrectomy: A narrative review"],"prefix":"10.4103","volume":"74","author":[{"given":"Ramanuj","family":"Samanta","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, AIIMS, Rishikesh, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabia","family":"Handa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, AIIMS, Bhatinda, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin Kumar","family":"Menia","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, AIIMS, Jammu, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavendra Rao","family":"Kolavali","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, AIIMS, Bibinagar, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"R1-20261103","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"R2-20261103","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: Systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"R3-20261103","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.4103\/ijo.IJO_1310_21","article-title":"Prevalence of diabetic retinopahty in India: Results from the National Survey 2015-19","volume":"69","author":"Vashist","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R4-20261103","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"R5-20261103","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"R6-20261103","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N Engl J Med"},{"key":"R7-20261103","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"key":"R8-20261103","first-page":"635","article-title":"Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: Results of a randomized trial\u2014ETDRS Report No. 23","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"R9-20261103","first-page":"51","article-title":"Vitreoretinal surgery in diabetic retinopathy","volume":"62","author":"Gupta","year":"2014","journal-title":"Indian J Ophthalmol"},{"key":"R10-20261103","first-page":"142","article-title":"Advances in vitreoretinal surgery for diabetic retinopathy","volume":"30","author":"Steel","year":"2016","journal-title":"Eye (Lond)"},{"key":"R11-20261103","first-page":"1","article-title":"Surgical management of diabetic tractional retinal detachment","volume":"56","author":"Tan","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"R12-20261103","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/jamaophthalmol.2024.1844","article-title":"Progression to pars plana vitrectomy in patients with proliferative diabetic retinopathy","volume":"142","author":"Alsoudi","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R13-20261103","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R14-20261103","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/eye.2008.354","article-title":"Can a preoperative bevacizumab injection prevent recurrent post vitrectomy diabetic vitreous haemorrhage?","volume":"23","author":"Romano","year":"2009","journal-title":"Eye (Lond)"},{"key":"R15-20261103","doi-asserted-by":"crossref","first-page":"18880","DOI":"10.1038\/s41598-020-75896-8","article-title":"Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: A network meta-analysis","volume":"10","author":"Wang","year":"2020","journal-title":"Sci Rep"},{"key":"R16-20261103","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ajo.2019.05.007","article-title":"Preoperative bevacizumab for tractional retinal detachment in proliferative diabetic retinopathy: A prospective randomized clinical trial","volume":"207","author":"Arevalo","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R17-20261103","first-page":"1408","article-title":"Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy","volume":"22","author":"Yeoh","year":"2008","journal-title":"Eye (Lond)"},{"key":"R18-20261103","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00417-008-0774-y","article-title":"Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)","volume":"246","author":"Rizzo","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R19-20261103","first-page":"25158414211059256","article-title":"Intravitreal bevacizumab prior to vitrectomy for proliferative diabetic retinopathy: A systematic review","volume":"14","author":"Dervenis","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"R20-20261103","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40942-023-00467-8","article-title":"Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: The Alvaro Rodriguez lecture 2023","volume":"9","author":"Arevalo","year":"2023","journal-title":"Int J Retina Vitreous"},{"key":"R21-20261103","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/eye.2011.149","article-title":"Bevacizumab prior to vitrectomy for diabetic traction retinal detachment","volume":"25","author":"Pokroy","year":"2011","journal-title":"Eye (Lond)"},{"key":"R23-20261103","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/eye.2017.75","article-title":"Ranibizumab pretreatment in diabetic vitrectomy: A pilot randomised controlled trial (the RaDiVit study)","volume":"31","author":"Comyn","year":"2017","journal-title":"Eye (Lond)"},{"key":"R24-20261103","doi-asserted-by":"crossref","first-page":"1067670","DOI":"10.3389\/fpubh.2022.1067670","article-title":"Prophylactic intravitreal injection of aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: A randomized controlled trial","volume":"10","author":"Qu","year":"2023","journal-title":"Front Public Health"},{"key":"R25-20261103","doi-asserted-by":"crossref","first-page":"2473234","DOI":"10.1155\/2016\/2473234","article-title":"A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy","volume":"2016","author":"Yang","year":"2016","journal-title":"J Ophthalmol"},{"key":"R26-20261103","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.18240\/ijo.2022.10.09","article-title":"Optimal timing of preoperative intravitreal anti-VEGF injection for proliferative diabetic retinopathy patients","volume":"15","author":"Xu","year":"2022","journal-title":"Int J Ophthalmol"},{"key":"R27-20261103","first-page":"CD008214","article-title":"Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy","author":"Smith","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R28-20261103","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ophtha.2006.07.047","article-title":"Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy","volume":"114","author":"Yang","year":"2007","journal-title":"Ophthalmology"},{"key":"R29-20261103","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ophtha.2007.08.034","article-title":"Entry site neovascularization and vitreous cavity hemorrhage after diabetic vitrectomy. The predictive value of inner sclerostomy site ultrasonography","volume":"115","author":"Steel","year":"2008","journal-title":"Ophthalmology"},{"key":"R30-20261103","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1755-3768.2009.01821.x","article-title":"Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy","volume":"89","author":"Yeh","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"R31-20261103","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00417-010-1303-3","article-title":"Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy","volume":"248","author":"di Lauro","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R32-20261103","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ophtha.2008.11.005","article-title":"Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment","volume":"116","author":"Oshima","year":"2009","journal-title":"Ophthalmology"},{"key":"R33-20261103","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/112067210901900526","article-title":"Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy","volume":"19","author":"Modarres","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"R34-20261103","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/112067211002000604","article-title":"Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy","volume":"20","author":"Hern\u00e1ndez-Da Mota","year":"2010","journal-title":"Eur J Ophthalmol"},{"key":"R35-20261103","doi-asserted-by":"crossref","first-page":"e2731","DOI":"10.1097\/MD.0000000000002731","article-title":"Evaluation of intravitreal ranibizumab on the surgical outcome for diabetic retinopathy with tractional retinal detachment","volume":"95","author":"Dong","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R36-20261103","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/IAE.0000000000000900","article-title":"Intravitreal conbercept (kh902) for surgical treatment of severe proliferative diabetic retinopathy","volume":"36","author":"Su","year":"2016","journal-title":"Retina"},{"key":"R37-20261103","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/jpm13040572","article-title":"Effect of intravitreal conbercept injection on complications of pars plana vitrectomy in patients with proliferative diabetic retinopathy","volume":"13","author":"Ding","year":"2023","journal-title":"J Pers Med"},{"key":"R38-20261103","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/bjo.2008.151233","article-title":"Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study)","volume":"93","author":"da R Lucena","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R39-20261103","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1167\/iovs.65.4.37","article-title":"Short term effect of pre-operative anti-VEGF on angiogenic and fibrotic profile of fibrovascular membranes of proliferative diabetic retinopathy","volume":"65","author":"Fadakar","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R40-20261103","first-page":"709","article-title":"Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy","volume":"2","author":"El-Batarny","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"R41-20261103","first-page":"CD008214","article-title":"Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy","volume":"5","author":"Dervenis","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"R42-20261103","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/02713683.2024.2409883","article-title":"Complications of silicone oil as vitreous tamponade in pars plana vitrectomy: A mini review","volume":"50","author":"Oliveira","year":"2025","journal-title":"Curr Eye Res"},{"key":"R43-20261103","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/01.iae.0000225351.87205.69","article-title":"Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy","volume":"26","author":"Chen","year":"2006","journal-title":"Retina"},{"key":"R44-20261103","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1097\/IAE.0b013e31820a68e5","article-title":"Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage","volume":"31","author":"Farahvash","year":"2011","journal-title":"Retina"},{"key":"R45-20261103","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.ophtha.2009.07.001","article-title":"Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: A randomized clinical trial","volume":"116","author":"Ahmadieh","year":"2009","journal-title":"Ophthalmology"},{"key":"R46-20261103","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1007\/s40123-023-00803-z","article-title":"Combined use of anti-VEGF drugs before and during pars plana vitrectomy for severe proliferative diabetic retinopathy","volume":"12","author":"Sun","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"R47-20261103","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1186\/s12886-025-04327-x","article-title":"Intravitreal anti-vascular endothelial growth factor agents as an adjunct for proliferative diabetic retinopathy: A systematic review and meta-analysis","volume":"25","author":"Song","year":"2025","journal-title":"BMC Ophthalmol"},{"key":"R48-20261103","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ophtha.2011.03.036","article-title":"The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy","volume":"118","author":"Ahn","year":"2011","journal-title":"Ophthalmology"},{"key":"R49-20261103","doi-asserted-by":"crossref","first-page":"e7512","DOI":"10.5867\/medwave.2019.01.7511","article-title":"Preoperative intravitreal bevacizumab for proliferative diabetic retinopathy patients undergoing vitrectomy-First update","volume":"19","author":"P\u00e9rez-Argando\u00f1a","year":"2019","journal-title":"Medwave"},{"key":"R50-20261103","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1159\/000530231","article-title":"A systematic review and meta-analysis of clinical outcomes of small gauge vitrectomy with or without intravitreal anti-vascular endothelial growth factor agents pretreatment for proliferative diabetic retinopathy","volume":"66","author":"Pei","year":"2023","journal-title":"Ophthalmic Res"},{"key":"R51-20261103","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/bjophthalmol-2017-311344","article-title":"Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: A meta-analysis of randomised controlled trials","volume":"102","author":"Zhao","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R52-20261103","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.survophthal.2021.03.001","article-title":"Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: A review","volume":"66","author":"Tan","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"R53-20261103","doi-asserted-by":"crossref","first-page":"e2675","DOI":"10.1371\/journal.pone.0002675","article-title":"The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy","volume":"3","author":"Kuiper","year":"2008","journal-title":"PLoS One"},{"key":"R54-20261103","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/IAE.0b013e3182753b41","article-title":"Altered vascular microenvironment by bevacizumab in diabetic fibrovascular membrane","volume":"33","author":"Nakao","year":"2013","journal-title":"Retina"},{"key":"R55-20261103","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2007.127142","article-title":"Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy","volume":"92","author":"Arevalo","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R56-20261103","first-page":"69","article-title":"Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy","volume":"9","author":"Zlotcavitch","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"R57-20261103","doi-asserted-by":"crossref","first-page":"23839","DOI":"10.1038\/s41598-021-03239-2","article-title":"Full-thickness macular hole formation in proliferative diabetic retinopathy","volume":"11","author":"Tsui","year":"2021","journal-title":"Sci Rep"},{"key":"R58-20261103","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/eye.2008.99","article-title":"Bevacizumab (Avastin) as a surgical adjunct in diabetic vitrectomy for fibrovascular disease","volume":"23","author":"Gandhi","year":"2009","journal-title":"Eye (Lond)"},{"key":"R59-20261103","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/bjo.2008.139378","article-title":"Retinal detachment with macular hole following intravitreal bevacizumab in patient with severe proliferative diabetic retinopathy","volume":"92","author":"Mitamura","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R60-20261103","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11892-022-01491-y","article-title":"Systemic and ocular adverse events with intravitreal anti-VEGF therapy used in the treatment of diabetic retinopathy: A review","volume":"22","author":"Zehden","year":"2022","journal-title":"Curr Diab Rep"},{"key":"R61-20261103","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"R62-20261103","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s40123-025-01157-4","article-title":"Systemic effects of intravitreal anti-VEGF therapy: A review of safety across organ systems","volume":"14","author":"Banerjee","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"R63-20261103","first-page":"727","article-title":"Vascular permeability induced by VEGF family members in vivo: Role of endogenous PAF and NO synthesis","volume":"100","author":"Brkovic","year":"2007","journal-title":"J Cell Bio-chem"},{"key":"R64-20261103","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1172\/JCI97192","article-title":"The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction","volume":"128","author":"Vieira","year":"2018","journal-title":"J Clin Invest"},{"key":"R65-20261103","first-page":"25158414221090103","article-title":"Is perioperative blood pressure monitoring during intravitreal injections important?","volume":"14","author":"Debbarma","year":"2022","journal-title":"Ther Adv Ophthalmol"},{"key":"R66-20261103","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1681\/ASN.2005080810","article-title":"Vascular endothelial growth factor A signaling in the podocyte\u2013endothelial compartment is required for mesangial cell migration and survival","volume":"17","author":"Eremina","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R67-20261103","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.2014010060","article-title":"Tubulovascular cross-talk by vascular endothelial growth factor A maintains peritubular microvasculature in the kidney","volume":"26","author":"Dimke","year":"2015","journal-title":"J Am Soc Nephrol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3360_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:00:27Z","timestamp":1793732427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3360_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3360_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"2025-12-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}